Fate Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, disclosing operational and financial information for its iPSC-derived cell therapy pipeline.
Key Highlights
- Shares outstanding: As of October 30, 2026, 121,568,755 shares of common stock, par value $0.001 per share, were issued and outstanding, according to the filing.
- Filer classification: The company identified itself as a non-accelerated filer and a smaller reporting company, not a large accelerated filer or emerging growth company.
- iPSC platform: The company disclosed it has multiple iPSC-derived cell product candidates currently undergoing clinical and nonclinical development.
- Funding risk: The filing stated that development of product candidates "will require substantial additional funding, which, if available, may cause dilution to our stockholders."
- Pipeline prioritization: The company disclosed it may deprioritize or discontinue clinical development of one or more product candidates for various reasons, including data from ongoing trials and competitive considerations.
- Exchange listing: The common stock trades on the Nasdaq Global Market under the symbol FATE (NASDAQ:FATE).
Fate Therapeutics Discloses iPSC Pipeline Risks and Share Count for September 30, 2026 Quarter
Fate Therapeutics, Inc., headquartered at 12278 Scripps Summit Drive, San Diego, CA 92131, filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC. The filing reports that as of October 30, 2026, the company had 121,568,755 shares of common stock outstanding at a par value of $0.001 per share. The company is incorporated in Delaware and carries IRS Employer Identification Number 65-1311552.
According to the filing, Fate Therapeutics relies on its proprietary induced pluripotent stem cell (iPSC) product platform to produce what it describes as "next-generation product candidates," with multiple iPSC-derived candidates in both clinical and nonclinical development. The filing notes that the company uses iPSC technology and gene-editing technology in creating its product candidates, and that inability to use these technologies "would significantly harm" the business. The filing also discloses that the company may elect to prioritize clinical development of a candidate in one disease area over another.
The filing's risk factor summary highlights several material uncertainties, including that "development of our product candidates will require substantial additional funding," that the regulatory approval process for novel candidates is "particularly uncertain," and that initial or interim clinical data "may change as more data become available." The company further disclosed dependence on third-party and sole-source suppliers for equipment and components used in product candidate production. The filing also cited potential impacts from federal legislative and regulatory efforts, including tariffs on pharmaceutical products, as risks to the business.
What Was Disclosed
Fate Therapeutics filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, reporting 121,568,755 shares outstanding as of October 30, 2026, and disclosing risks associated with its iPSC-based cell therapy pipeline, funding requirements, and regulatory uncertainties.



Please wait processing your request...